ArticleAmerican journal of respiratory and critical care medicine2019
Advancing Translational Science for Pulmonary Nontuberculous Mycobacterial Infections. A Road Map for Research.
Abstract read
In one paragraph
Article in American journal of respiratory and critical care medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 3 pooled it
5.2field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 3 syntheses or guidelines pooled it, 64 citations in OpenAlex.
- From Bench to Bedside: Evolving Definitions of Translational Research.Saudi medical journal · 2026Pooled it
- Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Guideline
- Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline.The European respiratory journal · 2020Guideline
- Validation of a respiratory symptom score from the Quality of Life-Bronchiectasis Questionnaire in adults withPatient related outcome measures · 2026Article
- Immunopathological outcomes are isolate dependent in chronic Mycobacterium avium complex pulmonary disease.Disease models & mechanisms · 2026Article
- Immunity AgainstVaccines · 2025Article
- Transcriptional and cytokine signatures of Mycobacterium abscessus complex pulmonary disease during disease progression and treatment.PLoS neglected tropical diseases · 2025Article
- C3HeB/FeJ mice with chronicMycobacteria (London, England) · 2025Article
- Nitric oxide-releasing prodrug for the treatment of complexAntimicrobial agents and chemotherapy · 2024Article
- Article
- Treatable traits and challenges in the clinical management of non-tuberculous mycobacteria lung disease in people with cystic fibrosis.Respiratory research · 2023Review
- Disruption of nontuberculous mycobacteria biofilms induces a highly vulnerable to antibiotic killing phenotype.Biofilm · 2023Article
- Unveiling the Clinical Diversity in Nontuberculous Mycobacteria (NTM) Infections: A Comprehensive Review.Cureus · 2023Review
- Reduced Sphingosine in Cystic Fibrosis Increases Susceptibility toInternational journal of molecular sciences · 2023Article
- A Leucyl-tRNA Synthetase Inhibitor with Broad-Spectrum Anti-Mycobacterial Activity.Antimicrobial agents and chemotherapy · 2023Article
- Environmental risk of nontuberculous mycobacterial infection: Strategies for advancing methodology.Tuberculosis (Edinburgh, Scotland) · 2023Article
- Repurposing β-Lactams for the Treatment ofAntibiotics (Basel, Switzerland) · 2023Article
- Microbiological profile, preclinical pharmacokinetics and efficacy of CRS0393, a novel antimycobacterial agent targeting MmpL3.Tuberculosis (Edinburgh, Scotland) · 2023Article
- Immunogenicity and protection against Mycobacterium avium with a heterologous RNA prime and protein boost vaccine regimen.Tuberculosis (Edinburgh, Scotland) · 2023Article
- Mycobacterium tuberculosis DprE1 Inhibitor OPC-167832 Is Active against Mycobacterium abscessusAntimicrobial agents and chemotherapy · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 18 institutions in 4 countries.
Shelby Daniel-Wayman1 Epidemiology Unit, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases.
Getahun Abate2 Division of Infectious Diseases, Allergy, and Immunology, Department of Internal Medicine, Saint Louis University, Saint Louis, Missouri.
Daniel L Barber3 T Lymphocyte Biology Unit, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases.
Luiz E Bermudez4 Department of Biomedical Sciences and.
Rhea N Coler6 Infectious Disease Research Institute, Seattle, Washington.
Michael H Cynamon8 Veterans Administration Medical Center, Syracuse, New York.
Charles L Daley10 Division of Mycobacterial and Respiratory Infections, Department of Medicine.
Rebecca M Davidson11 Center for Genes, Environment, and Health, and.
Thomas Dick12 Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
R Andres Floto14 Department of Medicine, University of Cambridge, Cambridge, United Kingdom.
Emily Henkle15 OHSU-PSU School of Public Health and.
Steven M Holland16 Division of Intramural Research, National Institute of Allergy and Infectious Diseases.
Mary Jackson17 Mycobacteria Research Laboratories, Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, Colorado.
Richard E Lee18 Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, Tennessee.
Eric L Nuermberger19 Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Kenneth N Olivier21 Laboratory of Chronic Airway Infection, Pulmonary Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, and.
Diane J Ordway17 Mycobacteria Research Laboratories, Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, Colorado.
D Rebecca Prevots1 Epidemiology Unit, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases.
James C Sacchettini22 Department of Biochemistry and Biophysics, Texas A&M University, College Station, Texas.
Max Salfinger23 Mycobacteriology and Pharmacokinetics Laboratories, National Jewish Health, Denver, Colorado.
Christopher M Sassetti25 Department of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, Massachusetts; and.
Christine F Sizemore26 Tuberculosis, Leprosy, and other Mycobacterial Diseases Program, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland.
Kevin L Winthrop15 OHSU-PSU School of Public Health and.
Adrian M Zelazny28 Microbiology Service, Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland.
National Institute of Allergy and Infectious Diseases · USColorado State University · USEkaterinburg Research Institute of Viral Infections · RUJohns Hopkins Medicine · USNational Heart Lung and Blood Institute · USNational Institutes of Health · USNational Institutes of Health Clinical Center · USNational University of Singapore · SGOregon Health & Science University · USOregon State University · USSaint Louis University · USSt. Jude Children's Research Hospital · USSUNY Upstate Medical University · USTexas A&M University · USUniversity of Cambridge · GBUniversity of Colorado Denver · USUniversity of Massachusetts Chan Medical School · USUniversity of Washington · US
Funding
Bronchiectasis and chronic airway infectionZIAHL006200 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI FENNELLY, KEVIN · 2015 to 2025
$25.1MGenes And Gene Products As ImmunoadjuvantsZIAAI000647 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI HOLLAND, STEVEN · 2009 to 2025
$22.6MTransgenic Animal Models Of Human Immune DefectsZIAAI000646 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI HOLLAND, STEVEN · 2009 to 2025
$22.2MImmune Regulation in Mycobacterial InfectionsZIAAI001171 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI BARBER, DANIEL · 2012 to 2025
$16.7MEpidemiology of Mycobacterial InfectionsZIAAI001035 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI PREVOTS, D. REBECCA · 2009 to 2025
$11.6MSystems Genetics of TuberculosisP01AI132130 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI BEHAR, SAMUEL M · 2017 to 2021
$11.2MDiscovery of novel lead-target pairs and identification of all-oral bactericidal drug regimens for Mycobacterium abscessus lung diseaseR01AI132374 · NIAID · RBHS-NEW JERSEY MEDICAL SCHOOL · PI Thomas Dick · 2018 to 2026
$7.0MExploiting a robust drug discovery portfolio to develop effective regimens to treat Mycobacterium abscessus lung infectionR21AI137814 · NIAID · JOHNS HOPKINS UNIVERSITY · PI NUERMBERGER, ERIC L · 2018 to 2019
$450kMolecular and Virulence Traits of Bacteria & Fungi Causing Persistent InfectionsZIACL080013 · CLC · CLINICAL CENTER · PI ZELAZNY, ADRIAN MARCELO · 2009 to 2025
$0kNIAID NIH HHS P01 AI132130NIAID NIH HHS R01 AI132374NIAID NIH HHS R21 AI137814
Abstract
PubMed holds no abstract for this paper.
Indexed as
Nontuberculous MycobacteriaTranslational Research, BiomedicalAnti-Bacterial AgentsDrug Resistance, BacterialHost-Pathogen InteractionsHumansMycobacterium Infections, NontuberculousAnti-Bacterial Agents
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.